MAPK7 and cancer: Moreover, we observed significant cancer cell death, accompanied by a reduction in mRNA levels of the cell proliferation marker, proliferating cell nuclear antigen (<i>PCNA</i>), following ERK5 inhibition due to MHJ-627 treatment.